Get the Stockscreener App
10.95
2.23%
-0.25
Rapport Therapeutics Inc stock is traded at $10.95, with a volume of 130.45K.
It is down -2.23% in the last 24 hours and up +9.94% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$11.20
Open:
$11.19
24h Volume:
130.45K
Relative Volume:
0.64
Market Cap:
$480.31M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-16.79%
1M Performance:
+9.94%
6M Performance:
-42.58%
1Y Performance:
-56.86%
1-Day Range:
$10.80
$11.39
1-Week Range:
$10.76
$13.39
52-Week Range:
$7.13
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
1325 BOYLSTON STREET, BOSTON
Compare RAPP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
10.95 | 480.31M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
Rapport Therapeutics Inc Stock (RAPP) Latest News
GAMMA Investing LLC Purchases 9,198 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Bank of America Corp DE Sells 12,532 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
California State Teachers Retirement System Purchases 7,886 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - MarketBeat
(RAPP) Long Term Investment Analysis - news.stocktradersdaily.com
Rapport Therapeutics management to meet with Citizens JMP - TipRanks
Deutsche Bank AG Invests $41,000 in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Stifel reiterates buy rating for Rapport Therapeutics stock By Investing.com - Investing.com Nigeria
Citizens JMP maintains positive outlook on Rapport Therapeutics stock By Investing.com - Investing.com UK
Rapport Therapeutics Completes Enrollment for Phase 2a Trial - TipRanks
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates - GlobeNewswire
Rapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical Pipeline - Nasdaq
How the (RAPP) price action is used to our Advantage - news.stocktradersdaily.com
Rapport Therapeutics to Participate in the Jefferies Global - GlobeNewswire
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference - Yahoo Finance
Rapport Therapeutics (RAPP) to Release Quarterly Earnings on Monday - Defense World
Rapport Therapeutics to Host 2025 Investor and Analyst Day - GlobeNewswire
Companies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In Growth - Yahoo Finance
Rapport Therapeutics Reports Q1 2025 Financial Results - MSN
Wells Fargo & Company MN Grows Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Barclays PLC Buys 5,634 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics, Inc. SEC 10-Q Report - TradingView
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update - The Manila Times
(RAPP) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Rapport Therapeutics (NASDAQ:RAPP) Shares Acquired by JPMorgan Chase & Co. - Defense World
Legal & General Group Plc Buys 8,614 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Acquired by Geode Capital Management LLC - Defense World
Rapport Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
When the Price of (RAPP) Talks, People Listen - news.stocktradersdaily.com
Rapport therapeutics chief scientific officer sells $81,310 of stock - Investing.com Australia
Rapport therapeutics chief scientific officer sells $81,310 of stock By Investing.com - Investing.com South Africa
KLP Kapitalforvaltning AS Purchases Shares of 1,900 Rapport Therapeutics (NASDAQ:RAPP) - Defense World
48,452 Shares in Rapport Therapeutics (NASDAQ:RAPP) Acquired by Norges Bank - Defense World
Comparing Rapport Therapeutics (RAPP) & The Competition - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at JMP Securities - Defense World
JMP Securities Initiates Coverage of Rapport Therapeutics (RAPP) with Market Outperform Recommendation - Nasdaq
Citizens JMP sets $28 target for Rapport Therapeutics stock By Investing.com - Investing.com Canada
(RAPP) Investment Analysis - news.stocktradersdaily.com
nCino Posts Weak Earnings, Joins Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Rapport Therapeutics: Too Early To Be Interesting (NASDAQ:RAPP) - Seeking Alpha
Swiss National Bank Purchases New Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Analyzing Neurogene (NASDAQ:NGNE) & Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Validea Kenneth Fisher Strategy Daily Upgrade Report3/25/2025 - Nasdaq
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):